secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tempus AI, Inc. (TEM)
CIK:        0001717115
Form:       8-K
Filed at:   2026-07-20T13:03:42+00:00
Accession:  0001193125-26-308469
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tempus AI to acquire Personalis for $1.5B, adding MRD technology to precision oncology platform
--------------------------------------------------------------------------------

- Total enterprise value of $1.5B net of Tempus' existing stake; $16.25 per share in stock, with Tempus option to pay up to 50% cash.
- Premium of 6% to Friday's close and 28% to 30-day VWAP; floating exchange ratio capped at 0.3356 Tempus shares per Personalis share.
- Closing expected late 2026 or early 2027, subject to Personalis shareholder approval, regulatory clearances, and customary conditions.
- Personalis reported Q2 preliminary revenue of $22.4M and 10,384 clinical tests, a 33% sequential increase in test volumes.
- Acquisition expands Tempus' reach in the $20B MRD market, combining Personalis' NeXT Personal test with Tempus' AI platform.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1717115/000119312526308469/0001193125-26-308469-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1717115/000119312526308469/d124162d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-308469

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer